Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

被引：0
|
作者：
Xiaoying Sun
Raheleh Roudi
Ting Dai
Shangya Chen
Bin Fan
Hongjin Li
Yaqiong Zhou
Min Zhou
Bo Zhu
Chengqian Yin
Bin Li
Xin Li
机构：
[1] Shanghai University of Traditional Chinese Medicine,Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
[2] Shanghai Academy of Traditional Chinese Medicine,Institute of Dermatology
[3] Iran University of Medical Sciences,Oncopathology Research Center
[4] Shandong Academy of Occupational Health and Occupational Medicine,Department of Toxicology
[5] Shandong Academy of Medical Science,Department of Pharmacology & Experimental Therapeutics
[6] Boston University School of Medicine,Department of Dermatology
[7] Shaanxi Traditional Chinese Medicine Hospital,undefined
来源：
BMC Cancer | / 19卷
关键词：
Non-small cell lung cancer; Oncology; Programmed cell death protein-1; Programmed cell death ligand 1; Inhibitor; Immune-related adverse event; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
    Banerjee, Debasree
    Monaghan, Sean
    Zhao, Runping
    Walsh, Thomas
    Palmisciano, Amy
    Phillips, Gary S.
    Opal, Steven
    Levy, Mitchell M.
    CRITICAL CARE, 2018, 22
  • [22] Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
    Debasree Banerjee
    Sean Monaghan
    Runping Zhao
    Thomas Walsh
    Amy Palmisciano
    Gary S. Phillips
    Steven Opal
    Mitchell M. Levy
    Critical Care, 22
  • [23] Immune-Related Gastrointestinal Adverse Events Associated With Anti-programmed Cell Death Antibodies: A Meta-Analysis
    Chris-Olaiya, Abimbola
    Allen, Steven
    Nambudiri, Vinod
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S82 - S83
  • [24] Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer
    Cui, Shaohua
    Su, Xinying
    Dong, Lili
    Qian, Jialin
    Ye, Lin
    Zhang, Tianwei
    Fu, Haihua
    Han, Hulin
    Huang, Jiaqi
    Yao, Yihong
    Gu, Yi
    Jiang, Liyan
    JOURNAL OF CANCER, 2017, 8 (19): : 4075 - 4082
  • [25] Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors
    Oyanagi, Jun
    Koh, Yasuhiro
    Sato, Koichi
    Teraoka, Shunsuke
    Tokudome, Nahomi
    Hayata, Atsushi
    Akamatsu, Hiroaki
    Ozawa, Yuichi
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    CLINICAL LUNG CANCER, 2021, 22 (06) : E833 - E841
  • [26] Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer
    Villaruz, Liza C.
    Blumenschein Jr, George R.
    Otterson, Gregory A.
    Leal, Ticiana A.
    CANCER, 2023, 129 (09) : 1319 - 1350
  • [27] The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients A systematic review and meta-analysis
    Li, Mingkai
    Huang, Linlin
    Ren, Xiuhong
    Liu, Lixia
    Shi, Qinghong
    Liu, Ling
    Wang, Xiao
    Tian, Yuan
    Yu, Lili
    Mi, Fuli
    MEDICINE, 2020, 99 (42) : E22555
  • [28] The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
    Guan, Xiuwen
    Wang, Haijuan
    Ma, Fei
    Qian, Haili
    Yi, Zongbi
    Xu, Binghe
    MEDICINE, 2016, 95 (11)
  • [29] Programmed death ligand-1 expression in non-small cell lung cancer
    Velcheti, Vamsidhar
    Schalper, Kurt A.
    Carvajal, Daniel E.
    Anagnostou, Valsamo K.
    Syrigos, Konstantinos N.
    Sznol, Mario
    Herbst, Roy S.
    Gettinger, Scott N.
    Chen, Lieping
    Rimm, David L.
    LABORATORY INVESTIGATION, 2014, 94 (01) : 107 - 116
  • [30] Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review
    Choi, Franchesca D.
    Kraus, Christina N.
    Elsensohn, Ashley N.
    Carley, Sama K.
    Lehmer, Larisa M.
    Nguyen, Rebecca T.
    Linden, Kenneth G.
    Shiu, Jessica
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 440 - 459
12345